[HTML][HTML] Target-based small molecule drug discovery for colorectal cancer: a review of molecular pathways and in silico studies
Colorectal cancer is one of the most prevalent cancer types. Although there have been
breakthroughs in its treatments, a better understanding of the molecular mechanisms and …
breakthroughs in its treatments, a better understanding of the molecular mechanisms and …
[HTML][HTML] Gaussian field-based 3D-QSAR and molecular simulation studies to design potent pyrimidine–sulfonamide hybrids as selective BRAF V600E inhibitors
The “RAS-RAF-MEK-ERK” pathway is an important signaling pathway in melanoma.
BRAFV600E (70–90%) is the most common mutation in this pathway. BRAF inhibitors have …
BRAFV600E (70–90%) is the most common mutation in this pathway. BRAF inhibitors have …
[HTML][HTML] Docking-based strategy to design novel flavone-based arylamides as potent V600E-BRAF inhibitors with prediction of their drug-likeness and ADMET …
Abstract Background V600E-BRAF protein target has much potential for scientific research
as therapeutic target due to its involvement in human melanoma cancer. In the current …
as therapeutic target due to its involvement in human melanoma cancer. In the current …
[HTML][HTML] BRAFV600E; K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy
L Porcelli, R Di Fonte, CL Pierri, L Fucci… - Pharmacological …, 2022 - Elsevier
The V600E mutation in BRAF is associated with increased phosphorylation of Erk1/2 and
high sensitivity to BRAFi/MEKi combination in metastatic melanoma. In very few patients, a …
high sensitivity to BRAFi/MEKi combination in metastatic melanoma. In very few patients, a …
Current insights into the role of BRAF inhibitors in treatment of melanoma
AK Singh, A Kumar, S Thareja… - Anti-Cancer Agents in …, 2023 - ingentaconnect.com
Melanomas represent only 4% of all skin cancers, but their mortality rate is more than 50% of
any other skin cancer. Alteration in genetic and environmental factors are the risk factors for …
any other skin cancer. Alteration in genetic and environmental factors are the risk factors for …
[HTML][HTML] Ligand based-design of potential schistosomiasis inhibitors through QSAR, homology modeling, molecular dynamics, pharmacokinetics, and DFT studies
Schistosomiasis, also known as bilharzia or snail fever, is a tropical disease caused by
parasitic flatworms belonging to the Schistosoma genus. This disease remains a prevalent …
parasitic flatworms belonging to the Schistosoma genus. This disease remains a prevalent …
[HTML][HTML] Modelling PIP4K2A inhibitory activity of 1, 7-naphthyridine analogues using machine learning and molecular docking studies
PIP4K2A is a type II lipid kinase that catalyzed the rate-limiting step of the conversion of
phosphatidylinositol-5-phosphate (PI5P) into phosphatidylinositol 4, 5-bisphosphate (PI4 …
phosphatidylinositol-5-phosphate (PI5P) into phosphatidylinositol 4, 5-bisphosphate (PI4 …
[HTML][HTML] In Silico Pharmacokinetic Profiling of the Identified Bioactive Metabolites of Pergularia tomentosa L. Latex Extract and In Vitro Cytotoxic Activity via the …
AS Abouzied, MM Abd-Rabo, B Huwaimel… - Pharmaceuticals, 2022 - mdpi.com
The in vitro cytotoxic efficacy of plant latex from Pergularia tomentosa L. was studied using
five human cancer cell lines: HeLa cells (cervical carcinoma cells), A-549 (lung carcinoma) …
five human cancer cell lines: HeLa cells (cervical carcinoma cells), A-549 (lung carcinoma) …
[HTML][HTML] Computational evaluation of potent 2-(1H-imidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors
Abstract Background V600E-BRAF is a major protein target involved in various types of
human cancers. However, the acquired resistance of the V600E-BRAF kinase to the …
human cancers. However, the acquired resistance of the V600E-BRAF kinase to the …
Targeting EGFR, RSK1, RAF1, PARP2 and LIN28B for several cancer type therapies with newly synthesized pyrazole derivatives via a computational study
FE Bennani, L Doudach, K Karrouchi… - Journal of …, 2023 - Taylor & Francis
Cancer remains the leading cause of death in the world despite the significant
advancements made in anticancer drug discovery. This study is aimed to computationally …
advancements made in anticancer drug discovery. This study is aimed to computationally …